Effects of edaravone dexborneol on oxidative stress and prognosis of patients with ACI after intravenous thrombolysis
Objective:To explore the effects of edaravone dexborneol on oxidative stress and prognosis of patients with acute cerebral infarction(ACI)after intravenous thrombolysis.Methods:A total of 60 patients with ACI treated in the hospital were enrolled as the research objects between May 2021 and May 2023,and they were randomly divided into a control group(n=30)and a treatment group(n=30).The control group was administered alteplase intravenous thrombolysis and oral aspirin enteric-coated tablets,while the treatment group was additionally treated with edaravone dexborneol on the basis of the control group.Both groups were treated with 14 days as one course of treatment.The therapeutic effects,serum oxidative stress indices,inflammatory factors,and adverse reactions of the two groups were observed,and the prognosis was analyzed by follow-up for 12 weeks after treatment.Results:After treatment,there was no significant difference in the treatment response rate(80.00％vs 60.00％),incidence of adverse reactions(6.67％vs 13.33％),or prognosis(6.67％vs 13.33％)between the two groups(P＞0.05).Before treatment,there were no significant differences in the NIHSS score,BI score,and levels of serum superoxide dismutase(SOD),malondialdehyde(MDA),C-reactive protein(CRP),lipoprotein-associated phospholipase A2(LP-PLA2),and interleukin-6(IL-6)between the two groups(P＞0.05).After treatment,the BI score and serum SOD level increased,while the NIHSS score and levels of serum MDA,CRP,LP-PLA2,and IL-6 decreased in both groups(P＜0.05).After treatment,the BI score and serum SOD level in the treatment group were higher than those in the control group,while the NIHSS score and serum MDA,CRP,LP-PLA2,and IL-6 levels were lower than those in the control group(P＜0.05).Conclusions:Edaravone dexborneol can effectively improve the clinical curative effect of intravenous thrombolysis,relieve nerve tissue injury and oxidative stress,and reduce the incidence of adverse drug reactions.
万方数据
维普
